How GLP-1 Weight-Loss Medications Work: A Patient's Guide to the Brain and Body Pathways Behind Drugs Like Semaglutide and Tirzepatide

Table of Contents

• Key Points
• What Are GLP-1 Receptor Agonists and Why Does This Matter?
• How the Authors Searched the Medical Literature
• The GLP-1 Medications Available Today
• How These Drugs Work in the Brain (Central Mechanisms)
• How These Drugs Work in the Body (Peripheral Mechanisms)
• The Next Generation: Dual and Triple Co-Agonists
• Putting It All Together: What the Authors Concluded
• Clinical Implications: What This Means for Patients
• Limitations of This Review
• Practical Recommendations for Patients
• Source Information
• Frequently Asked Questions

Key Points

• GLP-1 medications promote weight loss by acting on the brain to suppress appetite and on the body to slow stomach emptying and improve metabolism.
• The brain's hypothalamus, brainstem, and reward system are all involved; GLP-1 enhances fullness signals and reduces food cravings.
• Peripheral effects include decreased ghrelin, increased satiety hormones, stable blood sugar, lower cholesterol, reduced fat inflammation, and increased calorie burning.
• Tirzepatide, a dual GLP-1/GIP co-agonist, is approved for weight loss and shows enhanced effectiveness; triple co-agonists are in development.
• Weight loss occurs gradually; nausea and fullness are common early side effects, and hunger returns if the medication is stopped without a maintenance plan.

What Are GLP-1 Receptor Agonists and Why Does This Matter?

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as an important class of medication for managing type 2 diabetes and obesity. These agents mimic the effects of natural GLP-1, a hormone your intestines produce in response to food intake. Natural GLP-1 is quickly inactivated by an enzyme called dipeptidyl peptidase 4 (DPP-4), which is partly why injected versions that resist breakdown are so useful. GLP-1 RAs activate the GLP-1 receptor, and through that receptor they do several things at once.

They enhance glucose-dependent insulin secretion, meaning the pancreas releases more insulin only when blood sugar rises. They also inhibit glucagon release, a hormone that otherwise raises blood sugar. They slow gastric emptying, which keeps food in the stomach longer. Perhaps most importantly for weight loss, GLP-1 RAs suppress appetite and enhance satiety (the feeling of fullness) by acting on the central nervous system, leading to reduced calorie intake and weight loss.

Because these drugs regulate both glucose metabolism and body weight, they have gained major attention for diabetes management and as weight-loss treatments for people without diabetes. Currently, three GLP-1-based agents — liraglutide, semaglutide, and tirzepatide — are approved for chronic weight management. Tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist, represents an important advancement, showing enhanced effectiveness in weight reduction. As new agents that target multiple metabolic pathways are expected to enter the market, researchers say there is a growing need to understand how both current and future therapies control hunger and energy balance. This review gives a comprehensive look at the central and peripheral mechanisms behind GLP-1 RA-induced weight loss, with insights meant to help clinicians and researchers optimize current and future obesity treatments.

How the Authors Searched the Medical Literature

This is a review article, meaning the authors did not run a new experiment or enroll new patients. Instead, they identified and analyzed existing research papers on the topic. The authors searched PubMed and Google Scholar using terms including "glucagon-like peptide-1 receptor agonists," "glucagon-like peptide-1-based therapies," "liraglutide," "semaglutide," "tirzepatide," "mechanisms of action," "obesity," "weight loss," "appetite regulation," "metabolic effects," and "energy expenditure."

The search covered literature from the start of each database through September 2024. The final reference list was then generated based on the originality and relevance of each paper to the broad scope of the review. Readers should know that this approach is selective rather than exhaustive — the authors chose studies they judged most informative for explaining mechanism.

The GLP-1 Medications Available Today

Several GLP-1-based medications are approved by the U.S. Food and Drug Administration (FDA). They fall into two broad classes: single GLP-1 receptor agonists and, more recently, dual co-agonists that also target the GIP receptor. Some products combine a GLP-1 RA with insulin. The table below summarizes the FDA-approved agents the review authors list, with their brand names, approved indications, and approval years.

Note that the same generic medication can have different brand names for diabetes versus weight management. Semaglutide, for example, is sold as Ozempic and Rybelsus for type 2 diabetes but as Wegovy for overweight and obesity. Likewise, tirzepatide is Mounjaro for diabetes and Zepbound for weight management. Talk to your clinician about which formulation is appropriate for your situation; insurance coverage and approval criteria often differ between the diabetes and weight-management versions.

How These Drugs Work in the Brain (Central Mechanisms)

Two Systems Control Food Intake: Homeostatic and Hedonic

Food intake is regulated by complex interactions among nutrients, hormones, neuropeptides (small protein-like molecules that nerve cells use to communicate), and many different areas of the brain. Researchers divide feeding control into two broad categories: homeostatic and nonhomeostatic, also called hedonic, feeding. Homeostatic feeding maintains your energy balance by adjusting food intake to stabilize energy stores. Hedonic feeding, in contrast, is driven by the pleasurable properties of food. This reward-driven system can override the homeostatic system and lead to overeating.

GLP-1 RAs appear to act on both systems. Understanding this dual action matters, because many patients struggle with food cravings even when their body has enough energy. By dampening the reward circuitry, these medications address a root cause of overeating rather than simply forcing calorie restriction.

The Brainstem: First Stop for Fullness Signals

Two brainstem regions are central to this process: the nucleus tractus solitarii and the area postrema. The nucleus tractus solitarii (NTS) receives signals from the gastrointestinal tract about nutrient intake. When GLP-1 RAs bind to GLP-1 receptors in the NTS, they enhance the activity of serotonergic neurons — nerve cells that release serotonin, a neurotransmitter (chemical messenger) involved in mood and appetite. This promotes a feeling of fullness and reduces the urge to eat. GLP-1 activation in the NTS is also associated with the release of glutamate, an excitatory neurotransmitter, which further amplifies signals sent to higher brain centers.

The area postrema, located nearby in the brainstem, is unusual in that it lacks a normal blood-brain barrier, the protective filter that keeps many blood-borne substances out of the brain. Because of this, the area postrema can detect circulating signals related to hunger and satiety directly from the bloodstream. Activating GLP-1 receptors in this region influences dopaminergic signaling — the dopamine system involved in motivation and reward — which can reduce the rewarding feeling of food intake and contribute to appetite suppression. The NTS and area postrema then pass these signals upward to the arcuate nucleus of the hypothalamus.

The Hypothalamus: The Brain's Appetite Control Center

The arcuate nucleus, located in the hypothalamus deep within the brain, contains two opposing types of neurons. Anorexigenic neurons suppress appetite, while orexigenic neurons stimulate it. Together they regulate the homeostatic control of eating. When GLP-1 RAs activate receptors in the hypothalamus, they trigger an increased release of appetite-suppressing peptides such as pro-opiomelanocortin (POMC). At the same time, they decrease the release of appetite-stimulating peptides including neuropeptide Y (NPY) and agouti-related peptide (AgRP).

This shift results in reduced food intake and increased energy expenditure. GLP-1 RAs also affect two other hypothalamic regions: the paraventricular nucleus and the lateral hypothalamus, both involved in regulating hunger and energy balance. In the paraventricular nucleus, GLP-1 signaling influences the release of corticotropin-releasing hormone, oxytocin, and thyrotropin-releasing hormone — all of which reduce food intake. In the lateral hypothalamus, GLP-1 RAs inhibit orexin-producing neurons, which are cells that normally stimulate appetite.

The Reward System: Why Food Cravings Diminish

The mesolimbic reward pathway includes areas such as the ventral tegmental area and the nucleus accumbens. This circuit is critical for processing rewarding stimuli, including food and drugs. When GLP-1 receptors in these areas are activated, the result is decreased dopamine release, which diminishes the rewarding sensation typically associated with food and substance use.

This reduction in reward response lowers the motivation to consume high-calorie, palatable foods. GLP-1 action in the mesolimbic system can also influence serotonin levels, which are associated with both mood and satiety. This broad neurotransmitter modulation contributes to the drugs' overall effect on reducing reward-driven behaviors and hedonic feeding — the eating we do for pleasure rather than for energy needs.

Satiety Signaling and Leptin: Making the Brain More Responsive to "Fullness" Hormones

Satiety signaling plays a crucial role in regulating hunger. Leptin is a hormone primarily produced by adipose tissue (body fat) that acts on the hypothalamus to reduce appetite and increase energy expenditure. In many people with obesity, the brain stops responding properly to leptin — a condition called leptin resistance. This is one reason why people with obesity often feel hungry despite having abundant fat stores.

Satiety signals from the gut and other peripheral tissues can enhance leptin sensitivity in the hypothalamus, meaning the brain responds more effectively to leptin and promotes satiety. GLP-1 RAs enhance leptin signaling by reducing leptin resistance, which increases the effectiveness of leptin in suppressing appetite. In everyday terms, these medications help restore the brain's ability to hear the body's "you are full" signal.

How These Drugs Work in the Body (Peripheral Mechanisms)

While the brain effects are dramatic, GLP-1 RAs also act throughout the body. The "peripheral" (outside-the-brain) mechanisms are just as important for weight loss and for overall metabolic health. These include changes in gut hormones, slower stomach emptying, better blood sugar control, healthier blood fat levels, and reduced inflammation in fat tissue.

Gut Hormone Regulation: Ghrelin, Peptide YY, and Cholecystokinin

Gut hormones such as ghrelin, peptide YY, and cholecystokinin play significant roles in regulating appetite and digestion. GLP-1 RA signaling modulates the secretion of these gastrointestinal hormones and enhances their effects on satiety.

Ghrelin is known as the "hunger hormone" because it stimulates appetite, increases food intake, and promotes fat storage. It is primarily produced and secreted by the stomach when the stomach is empty — essentially a signal that it's time to eat. GLP-1 RAs decrease ghrelin levels, which contributes to their appetite-suppressing effects. For patients, this means the drug quiets the biological alarm that triggers hunger between meals.

Peptide YY, produced in the intestines and colon, and cholecystokinin (CCK), produced in the small intestine, are both released from the gut in response to food intake. They act as potent satiety signals. Peptide YY signals satiety by slowing gastric emptying and reducing appetite. Cholecystokinin promotes digestion and inhibits further food intake by inducing a feeling of fullness. Researchers hypothesize that GLP-1 RAs enhance the release and action of peptide YY and cholecystokinin, amplifying their appetite-suppressing effects.

Delayed Gastric Emptying: Feeling Full Longer

Satiety signals are produced when mechanoreceptors (pressure sensors) in the stomach wall are activated by distension — the physical stretching of the stomach as it fills with food. These signals are relayed to the nucleus tractus solitarii in the brainstem via the vagal nerves, the main nerve highways connecting the gut and brain.

The amount of gastric distension caused by food is partly influenced by the rate of gastric emptying and gastric motility, both of which are significantly reduced when plasma GLP-1 levels are elevated. By slowing the rate at which food leaves the stomach and reducing gastric acid secretion, GLP-1 RAs prolong the sensation of fullness. This is why some patients describe a "dyspepsia" effect — a feeling of indigestion or uncomfortable fullness after eating. While unpleasant at first, this prolonged fullness translates directly into decreased hunger and reduced food intake.

Glucose Metabolism: Stabilizing Blood Sugar Quiets Hunger

GLP-1 RAs enhance glucose-dependent insulin secretion from the pancreas, helping to lower blood glucose levels and improve glycemic control (long-term blood sugar management). Importantly, this insulin release is glucose-dependent: the drug only stimulates insulin when blood sugar is elevated, which reduces the risk of dangerously low blood sugar (hypoglycemia) compared with some other diabetes medications.

GLP-1 RAs also inhibit the release of glucagon, reducing the liver's production of glucose (hepatic glucose production) and contributing to lower fasting glucose levels. Stable glucose levels minimize hunger signals sent by the brain, leading to a reduction in appetite and food intake. This creates a virtuous cycle: better blood sugar control supports the appetite-suppressing effects, which supports weight loss, which further improves blood sugar.

Lipid Benefits, Thermogenesis, and Fat Tissue Remodeling

GLP-1 RAs also improve lipid profiles by reducing triglycerides and low-density lipoprotein (LDL) cholesterol — the "bad" cholesterol linked to heart disease. Enhanced glycemic control and improved lipid metabolism lead to better mobilization and utilization of fat stores for energy, reducing the likelihood of excess fat accumulation.

GLP-1 RAs also increase thermogenesis, the process of heat production in the body, which further increases energy expenditure. In plain terms, the body burns more calories partly by generating more heat.

Beyond effects on blood fats, GLP-1 RAs improve the function of adipose tissue by reducing inflammation. Chronic inflammation in adipose tissue is a common feature of obesity and contributes to insulin resistance and metabolic dysfunction. Healthier adipose tissue is better at storing and releasing fats appropriately, which reduces ectopic fat deposition — the harmful buildup of fat in organs like the liver and muscle where it doesn't belong — and promotes weight loss.

GLP-1 RAs may also promote the redistribution of fat from visceral (abdominal) stores to subcutaneous depots. This distinction matters. Visceral fat, stored around internal organs, is more harmful and metabolically active. It contributes to many conditions, including type 2 diabetes and cardiovascular disease. Subcutaneous fat, stored just under the skin, is less dangerous metabolically. So even beyond the number on the scale, these drugs may shift fat toward a healthier pattern of storage. Taken together, these combined effects improve overall metabolic health and help sustain weight loss.

The Next Generation: Dual and Triple Co-Agonists

Dual and triple co-agonists represent an innovative approach in obesity treatment. These include combinations such as GLP-1/GIP, GLP-1/glucagon (GCG), and GLP-1/GIP/GCG. The idea is to combine different incretin pathways — incretins being the gut hormones that stimulate insulin release — to potentially enhance therapeutic effectiveness.

A co-agonist is a single molecule that targets multiple receptors, allowing the simultaneous activation of different pathways involved in metabolic control and appetite regulation. By leveraging the complementary effects of each hormone, dual and triple co-agonists may offer a more comprehensive approach to weight management. They potentially improve both glucose metabolism and energy balance more effectively than single agonists. For this reason, they are a major focus of ongoing research to determine their full potential in clinical settings.

GIP Receptor Agonists: Partners to GLP-1

GIP RAs contribute to weight loss by modulating both insulin and lipid metabolism. They enhance insulin secretion and decrease glucagon secretion, which helps regulate blood glucose levels. Beyond glucose control, GIP RAs influence fat metabolism by promoting lipogenesis (fat storage) in some tissues and inhibiting fat storage in others, potentially leading to a more favorable lipid profile. This tissue-specific effect is complex, but the overall result appears beneficial for metabolic health.

Recent studies suggest GIP RAs may also increase energy expenditure and improve metabolic flexibility — the body's ability to switch smoothly between burning glucose and burning fat as fuel, depending on what is available. When used in combination with GLP-1 RAs, GIP RAs may complement the appetite-suppressing and glucose-lowering effects, producing more effective weight loss through a synergistic impact on multiple metabolic pathways.

Glucagon Receptor Agonists: Tapping into Fat Burning

Glucagon receptor agonists (GCG RAs) aid in weight loss by enhancing fat metabolism and increasing energy expenditure. When activated, glucagon receptors stimulate lipolysis — the breakdown of stored fats into free fatty acids — which are then used as an energy source. This process reduces fat stores and increases overall energy expenditure, contributing to a negative energy balance essential for weight loss.

Additionally, GCG RAs can boost thermogenesis, further enhancing calorie burning. These effects distinguish them from the more direct appetite regulation mechanisms of GLP-1 RAs. One potential drawback is that GCG RAs can raise blood glucose levels through gluconeogenesis (making new glucose) and glycogenolysis (breaking down stored glycogen into glucose). However, this effect is typically more pronounced during fasting or when glucose levels are low. When combined with GLP-1 RAs — which lower blood glucose through insulin secretion and glucagon suppression — the glucose-raising effect of GCG RAs is largely mitigated, balancing the metabolic effects. The weight-loss effects of GCG RAs are primarily due to their ability to mobilize and use fat, making them a promising component of combination therapies for obesity management.

Putting It All Together: What the Authors Concluded

GLP-1 RAs and co-agonists contribute to weight loss through multiple interconnected physiological pathways. By acting on the central nervous system, they suppress appetite and enhance satiety signaling, leading to reduced calorie intake. They also delay gastric emptying, prolonging the feeling of fullness after meals.

Beyond appetite regulation, GLP-1 RAs and co-agonists enhance energy metabolism by improving glycemic control, promoting thermogenesis, and increasing energy expenditure. Their positive impact on lipid metabolism promotes healthier fat storage and utilization. These mechanisms, working together, make GLP-1 RAs and co-agonists effective for sustained weight loss — which the authors emphasize is essential for addressing obesity and its related complications.

As new agents targeting multiple metabolic pathways enter the market, their broader effects may yield more robust weight-loss outcomes. By activating additional pathways, dual and triple GLP-1 co-agonists may enhance efficacy. The authors conclude that further research into these pathways will be essential to optimize the clinical application of these therapies.

Clinical Implications: What This Means for Patients

For patients, the most important takeaway is that GLP-1 medications are not simple appetite suppressants. They work through a sophisticated, multi-level system that touches nearly every part of energy regulation. The clinical significance, highlighted in the original paper, is that GLP-1 receptor agonists promote weight loss by suppressing appetite, enhancing satiety, and delaying gastric emptying. They also modulate central neural pathways and peripheral metabolic processes, providing cardiometabolic benefits that go beyond weight reduction alone.

This matters for expectation-setting. When a patient starts semaglutide or tirzepatide, the weight loss they experience is not just from "eating less." The medication is simultaneously quieting reward-driven food cravings, amplifying fullness signals from the gut, changing how fat tissue stores and releases energy, improving the body's ability to use fat for fuel, and even increasing heat production. These are biological changes, not just behavioral ones.

Because the brain's reward circuitry is involved, patients may find that foods they once craved become less compelling. Because gastric emptying slows, they may feel full after smaller meals and for longer periods. Because fat tissue inflammation decreases, metabolic health can improve even before dramatic weight loss occurs. Understanding these mechanisms can help patients and clinicians have realistic conversations about how these drugs work, how quickly to expect results, and why side effects like nausea and fullness occur — especially in the early weeks of treatment as the body adjusts to slower stomach emptying.

The review also broadens the therapeutic landscape. Tirzepatide's approval as a dual GLP-1/GIP co-agonist in 2022 for diabetes and 2023 for obesity demonstrates that targeting additional pathways can enhance efficacy. For patients who have not achieved sufficient weight loss on a single-agent GLP-1 RA, dual co-agonists may offer another option. Even newer triple combinations are in development.

Limitations of This Review

This article is a narrative review, not a clinical trial. It presents no new patient data of its own. Instead, it synthesizes findings from previously published studies, some of which were conducted in animals rather than humans. For example, early experiments on GLP-1 receptor ligands like liraglutide and exendin-4 in rats helped establish that these drugs suppress food intake and body weight — but animal results do not always translate perfectly to people.

The search strategy, while thorough, was limited to two databases (PubMed and Google Scholar) and ended in September 2024. The authors selected references "based on originality and relevance to the broad scope of this review," meaning this is an expert synthesis rather than a fully systematic review with explicit inclusion criteria. It is possible that some relevant studies were not included. The review also discusses mechanisms that are still actively being investigated; some hypotheses, such as the idea that GLP-1 RAs enhance the release and action of peptide YY and cholecystokinin, are explicitly described by the authors as theories rather than established facts. Long-term outcomes and individual variation in response are areas that ongoing research continues to clarify.

Finally, readers should be aware of the authors' disclosures. Dr. Tsoukas has received speaker honoraria (payment for giving talks) from Novo Nordisk, Eli Lilly, Boehringer-Ingelheim, and Sanofi — all companies that make diabetes or obesity medications. The other authors reported no conflicts of interest. The research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors. These disclosures are standard practice and are provided so readers can weigh the information with full transparency.

Practical Recommendations for Patients

The following suggestions are grounded in the mechanisms this review describes. They are general guidance, not medical advice — always discuss your individual treatment plan with your healthcare provider.

1. Talk to your doctor about whether a GLP-1 RA is right for you. These medications are FDA-approved for type 2 diabetes and for chronic weight management in people with overweight or obesity. Your clinician can help determine whether your body mass index, metabolic health, and medical history make you a candidate.
2. Ask which formulation fits your goals. As the table shows, the same medication can be approved under different brand names for diabetes versus weight management. Ozempic and Wegovy both contain semaglutide, but they are prescribed at different doses and for different indications. Mounjaro and Zepbound both contain tirzepatide, with similar distinctions. Coverage and out-of-pocket costs often differ based on the indication.
3. Expect gastrointestinal effects in the first weeks. Because these drugs slow gastric emptying and reduce gastric acid secretion, nausea, fullness, and dyspepsia (indigestion) are common early side effects. Eating smaller meals, avoiding high-fat foods, and following your clinician's dose-escalation schedule can help your body adjust. These effects are a direct extension of the drug's mechanism — the same slowed emptying that causes discomfort is part of what makes you feel full longer.
4. Give the medication time. Weight loss from GLP-1 RAs occurs gradually over weeks to months. The brain's appetite circuitry, gut hormone responses, and fat tissue remodeling do not change overnight. Sustained weight loss, the review emphasizes, comes from the combined action of all these mechanisms working together over time.
5. Use the medication as part of a broader lifestyle plan. The drug reduces appetite and dampens food reward, but nutrition quality and physical activity still matter for long-term health. The review notes that GLP-1 RAs improve how the body mobilizes fat for energy and increase energy expenditure — behaviors like walking and strength training can complement these metabolic effects.
6. Ask about cardiometabolic benefits beyond the scale. According to the review, GLP-1 RAs reduce triglycerides and LDL cholesterol, reduce inflammation in fat tissue, improve glycemic control, and may shift fat away from harmful visceral stores. If you have type 2 diabetes, high cholesterol, or excess abdominal fat, these effects may matter as much as the weight number itself.
7. Stay informed about newer options. Dual and triple co-agonists targeting GLP-1 alongside GIP and glucagon pathways are emerging. Tirzepatide, already approved, is the first of this wave. If your current treatment plateaus, ask your clinician whether a dual co-agonist or an upcoming therapy might be worth considering.
8. Do not stop these medications without medical supervision. Appetite and hunger signals return when the drug is discontinued. If you and your clinician decide to stop, a plan for maintaining weight loss — including dietary strategies and follow-up — is essential.

Frequently Asked Questions

What conditions are GLP-1 medications like semaglutide approved for?

These medications are FDA-approved for type 2 diabetes and for chronic weight management in adults with overweight or obesity. The same generic medication may have different brand names for diabetes versus weight management. Your doctor can determine if your body mass index, metabolic health, and medical history make you a candidate.

How do GLP-1 receptor agonists cause weight loss?

They work through multiple pathways. In the brain, they suppress appetite, reduce food cravings, and increase fullness. In the body, they slow stomach emptying, stabilize blood sugar, reduce hunger hormones, improve fat metabolism, lower inflammation, and increase calorie burning. Weight loss occurs gradually as these combined effects reduce calorie intake and improve energy use.

Why do GLP-1 medications cause nausea and indigestion?

These drugs slow gastric emptying and reduce gastric acid secretion to make you feel full longer. This same mechanism can cause nausea, fullness, and dyspepsia, especially in the first weeks. Eating smaller meals, avoiding high-fat foods, and following your clinician's dose-escalation schedule can help your body adjust.

Are GLP-1 medications safe for people without diabetes?

Yes, certain GLP-1-based medications are approved for chronic weight management in people with overweight or obesity even without diabetes. Examples include semaglutide under the brand name Wegovy and tirzepatide as Zepbound. Your clinician can help determine whether these are appropriate based on your health profile.

What are dual co-agonists and how are they different?

Tirzepatide is a dual GLP-1/GIP receptor co-agonist, meaning it targets two metabolic pathways. It was approved for type 2 diabetes in 2022 and for weight management in 2023, showing enhanced weight reduction compared with single GLP-1 agonists. Newer triple co-agonists are also being researched.

Why do I still crave food even when my body has enough energy?

Food intake is controlled by both homeostatic and hedonic systems. Hedonic feeding is driven by food's pleasurable properties and can override energy needs. GLP-1 medications act on the brain's reward circuitry, reducing dopamine release and dampening cravings for high-calorie foods, addressing a root cause of overeating.

Should I get a second opinion before choosing a GLP-1 weight-loss medication like semaglutide or tirzepatide?

A second opinion is especially useful if you are unsure whether a single GLP-1 receptor agonist or a dual co-agonist is right for you. Tirzepatide, a dual GLP-1/GIP co-agonist, has shown enhanced effectiveness for weight reduction and is approved for overweight and obesity, so it may be appropriate if a single agent has not achieved sufficient weight loss. Also ask whether your situation requires the diabetes brand or the weight-management brand, because the same medication can have different approvals and doses. A second opinion can clarify alternatives, expected gastrointestinal effects, and whether a plateaued treatment warrants switching. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on peer-reviewed research published in The American Journal of Medicine, Volume 138, Issue 6, June 2025, pages 934–940. The original article is titled "Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation" by Areesha Moiz, MSc; Kristian B. Filion, PhD; Michael A. Tsoukas, MD; Oriana H.Y. Yu, MD, MSc; Tricia M. Peters, MD, PhD; and Mark J. Eisenberg, MD, MPH.

The authors are affiliated with the Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal; the Division of Experimental Medicine, McGill University; the Department of Epidemiology, Biostatistics and Occupational Health, McGill University; the Department of Medicine, McGill University; the Division of Endocrinology and Metabolism, McGill University; and the Division of Cardiology, Jewish General Hospital/McGill University, Canada.

The article is published by Elsevier Inc. under the CC BY-NC license and is an open-access article (http://creativecommons.org/licenses/by-nc/4.0/). Its DOI is https://doi.org/10.1016/j.amjmed.2025.01.021. The research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This patient summary was prepared to help non-specialist readers understand the review's findings. In cases where this summary and the original article differ, the original peer-reviewed article is the authoritative source.